• VolitionRx highlighted an asset-light strategy focused on commercial partnerships and out-licensing of its Nu.Q platform across cancer, sepsis, and veterinary testing.
• Outlined a potential USD 5 million contractual milestone tied to publication of a submitted feline study paper.
• Reported USD 23 million in licensing to date, with revenue of USD 1 million in Q1 2026.
• Targeting multiple human-space licensing deals in 2026, following first deals signed in Q3 2025.
• Flagged reimbursement submission preparations for Nu.Q cancer assays, with an expectation of routine clinical use in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.